Celltrion announced on February 7 that Ramsima SC (infliximab, subcutaneous) and Yuflyma (adalimumab) have won the recent national tender in Norway and are now available in the Norwegian market. Celltrion will supply both products to Norway for two years from this month through 2026.
Norway is a representative country in the Nordic region with a high level of medical welfare, and its healthcare system is centered on state-run hospitals, and most biopharmaceuticals are supplied through the national tender system.
In particular, the country's policies to encourage biosimilars and regulate drug prices are designed to improve patient access to healthcare and ease the government's financial burden, providing a favorable environment for Celltrion to expand prescriptions for its products.
Ramsima SC is the world's only subcutaneous formulation of infliximab with proven therapeutic efficacy and safety across the globe. The ease of self-administration at home is highly anticipated by healthcare providers and patients, and we expect a rapid uptake in Norway.
The companion product, Yuflyma, was also launched through a national tender and aims for rapid market penetration with the advantage of a higher concentration formulation that halves the drug dose compared to lower concentrations. It is also expected to secure a share of more than 30% this year due to its advantage over competing products by diversifying dosages such as 40mg/0.4mL and 80mg/0.8mL.
Both Ramsima SC and Yuflyma will be sold directly by local corporations. In particular, the local subsidiary will continue to secure actual prescription data for both products while consulting with the government and medical institutions to promote evidence-based marketing strategies.
In addition, the company is confident that its aggressive implementation of data-driven marketing strategies in neighboring countries will increase confidence in the products and ultimately lead to increased prescribing of Celltrion's medicines across the Nordic region.
Celltrion continues to strengthen its product lineup by participating in tender competitions for follow-on products such as Vegzelma (bevacizumab) in Norway, and plans to expand the launch of Ramsima SC to neighboring Nordic countries such as Denmark in the first half of this year.
"In the biosimilar-friendly Nordic region, Celltrion's products, including Ramsima SC and Yuflyma, are establishing themselves as leading treatments for autoimmune diseases based on their unique competitive advantages," said Seung-Doo Baek, President, Celltrion, Northern Europe. "As we look ahead to achievements across the globe, including the launch of Zymfentra (Ramsima SC U.S.) in the U.S., the world's largest pharmaceutical market, this year, we will continue to focus our marketing efforts to drive prescription expansion in Europe."
